Sanofi India Ltd (SANOFI) — shareholding pattern, promoter holding, financials and share price

About Sanofi India Ltd (SANOFI)

Sanofi India Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SANOFI and on the BSE under scrip code 500674. Its ISIN is INE058A01010.

Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines. [1]

Sanofi India Limited is a listed pharmaceutical company focused on manufacturing and marketing prescription medicines in India, with a strategic emphasis on diabetes care (insulin portfolio) and distribution partnerships for cardiovascular, CNS and oral anti‑diabetic categories; it operates manufacturing sites (notably Goa) and sells through independent distributors across domestic and select export markets.

The company completed a pivotal transformation in 2025: refocusing on insulin, launching a partnership model for legacy brands, and reorganizing around digital and AI‑enabled customer engagement, which management cites as the foundation for sustainable, profitable growth even as transitional effects impacted reported revenue and segmental comparability.

Listed peers in Pharmaceuticals: Sudeep Pharma Ltd, Sun Pharma Advanced Research Company Ltd, Jeena Sikho Lifecare Ltd, FDC Ltd, Supriya Lifescience Ltd, Senores Pharmaceuticals Ltd.

Valuation & Returns

10 Jul 2026

At ₹3,418 a share on 10 Jul 2026, Sanofi India Ltd (SANOFI) was valued at a price-to-earnings ratio of 21.79x against an industry P/E of 36.41x and a price-to-book of 9.15x on a book value of ₹373.68 per share as of Dec 2024. Solomo computes return on equity of 41.97% and return on capital employed of 56.11% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2024 to Mar 2025.

P/E
21.79x
Industry P/E
36.41x
P/B
9.15x
EPS (TTM)
₹156.83
Book value / share
₹373.68
ROE
41.97%
ROCE
56.11%
ROA
22.41%
Debt / equity
0.02x
Dividend yield
3.6%
EBITDA margin
28.27%
52-week range
₹3,057.6 – ₹6,025.45

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Dec 2024

In the year ended Dec 2024, Sanofi India Ltd (SANOFI) reported revenue of ₹2,013 crore, net profit of ₹413 crore and earnings per share of ₹179.7. That compares with revenue of ₹1,996 crore and net profit of ₹603 crore in Dec 2023. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2025, revenue was ₹535.9 crore and net profit ₹119.5 crore (consolidated).

Consolidated annual results for Sanofi India Ltd (SANOFI), Dec 2023 to Dec 2024. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricDec 2023Dec 2024
Revenue (₹ cr)1,9962,013
Net profit (₹ cr)603413
EPS (₹)262.13179.7
Compound annual growth for Sanofi India Ltd (SANOFI). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth-3.01%-8.74%-12.79%0.86%
Profit growth0.80%-7.31%-19.26%-31.45%
Stock price CAGR2%-7%-7%-42%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 60.4% of Sanofi India Ltd (SANOFI) (unchanged from the previous quarter), foreign institutional investors (FII) hold 5.69% and domestic institutional investors (DII) hold 19.87%. Market capitalisation was ₹7,872 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.

Largest disclosed public shareholders in Jun 2026: LIFE INSURANCE CORPORATION OF INDIA - P & GS Fund 5.95%, NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMALL CAP FUND 4.08%, GENERAL INSURANCE CORPORATION OF INDIA 2.56%, ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C - ADITYA BIRLA SUN LIFE MNC FUND 2.32%, SBI ELSS TAX SAVER FUND 1.73%, BAJAJ LIFE INSURANCE LIMITED 1.44%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202660.4%-5.69%19.87%39.6%
Mar 202660.4%-5.64%21.13%39.6%
Dec 202560.4%-5.55%21.31%39.6%
Sep 202560.4%-5.57%22.29%39.6%
Jun 202560.4%-5.61%23.06%39.6%
Mar 202560.4%-5.57%23.02%39.6%
Dec 202460.4%-5.63%22.93%39.6%
Sep 202460.4%-5.78%22.82%39.6%
Every quarter since Mar 2001 Filing data, not investment advice.